Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment

Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Roeska, Kerstin [verfasserIn] Seilheimer, Bernd

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2010

Schlagwörter:	Respiratory Syncytial Virus Antiviral Activity Respiratory Virus Antiviral Effect Test Preparation

Anmerkung:	© Roeska and Seilheimer; licensee BioMed Central Ltd. 2010

Übergeordnetes Werk:	Enthalten in: Journal of immune based therapies and vaccines - London : Biomed Central, 2003, 8(2010), 1 vom: 16. Nov.
Übergeordnetes Werk:	volume:8 ; year:2010 ; number:1 ; day:16 ; month:11

Links:	Volltext

DOI / URN:	10.1186/1476-8518-8-6

Katalog-ID:	SPR029446600

Internformat


LEADER	01000caa a22002652 4500
001	SPR029446600
003	DE-627
005	20230519123824.0
007	cr uuu---uuuuu
008	201007s2010 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/1476-8518-8-6 \|2 doi
035			\|a (DE-627)SPR029446600
035			\|a (SPR)1476-8518-8-6-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Roeska, Kerstin \|e verfasserin \|4 aut
245	1	0	\|a Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment
264		1	\|c 2010
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010
520			\|a Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response.
650		4	\|a Respiratory Syncytial Virus \|7 (dpeaa)DE-He213
650		4	\|a Antiviral Activity \|7 (dpeaa)DE-He213
650		4	\|a Respiratory Virus \|7 (dpeaa)DE-He213
650		4	\|a Antiviral Effect \|7 (dpeaa)DE-He213
650		4	\|a Test Preparation \|7 (dpeaa)DE-He213
700	1		\|a Seilheimer, Bernd \|4 aut
773	0	8	\|i Enthalten in \|t Journal of immune based therapies and vaccines \|d London : Biomed Central, 2003 \|g 8(2010), 1 vom: 16. Nov. \|w (DE-627)362770271 \|w (DE-600)2100016-5 \|x 1476-8518 \|7 nnns
773	1	8	\|g volume:8 \|g year:2010 \|g number:1 \|g day:16 \|g month:11
856	4	0	\|u https://dx.doi.org/10.1186/1476-8518-8-6 \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 8 \|j 2010 \|e 1 \|b 16 \|c 11

Indexfelder

author_variant	k r kr b s bs
matchkey_str	article:14768518:2010----::niiaatvtoegsoadrpheai
hierarchy_sort_str	2010
publishDate	2010
allfields	10.1186/1476-8518-8-6 doi (DE-627)SPR029446600 (SPR)1476-8518-8-6-e DE-627 ger DE-627 rakwb eng Roeska, Kerstin verfasserin aut Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010 Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. Respiratory Syncytial Virus (dpeaa)DE-He213 Antiviral Activity (dpeaa)DE-He213 Respiratory Virus (dpeaa)DE-He213 Antiviral Effect (dpeaa)DE-He213 Test Preparation (dpeaa)DE-He213 Seilheimer, Bernd aut Enthalten in Journal of immune based therapies and vaccines London : Biomed Central, 2003 8(2010), 1 vom: 16. Nov. (DE-627)362770271 (DE-600)2100016-5 1476-8518 nnns volume:8 year:2010 number:1 day:16 month:11 https://dx.doi.org/10.1186/1476-8518-8-6 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2010 1 16 11
spelling	10.1186/1476-8518-8-6 doi (DE-627)SPR029446600 (SPR)1476-8518-8-6-e DE-627 ger DE-627 rakwb eng Roeska, Kerstin verfasserin aut Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010 Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. Respiratory Syncytial Virus (dpeaa)DE-He213 Antiviral Activity (dpeaa)DE-He213 Respiratory Virus (dpeaa)DE-He213 Antiviral Effect (dpeaa)DE-He213 Test Preparation (dpeaa)DE-He213 Seilheimer, Bernd aut Enthalten in Journal of immune based therapies and vaccines London : Biomed Central, 2003 8(2010), 1 vom: 16. Nov. (DE-627)362770271 (DE-600)2100016-5 1476-8518 nnns volume:8 year:2010 number:1 day:16 month:11 https://dx.doi.org/10.1186/1476-8518-8-6 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2010 1 16 11
allfields_unstemmed	10.1186/1476-8518-8-6 doi (DE-627)SPR029446600 (SPR)1476-8518-8-6-e DE-627 ger DE-627 rakwb eng Roeska, Kerstin verfasserin aut Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010 Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. Respiratory Syncytial Virus (dpeaa)DE-He213 Antiviral Activity (dpeaa)DE-He213 Respiratory Virus (dpeaa)DE-He213 Antiviral Effect (dpeaa)DE-He213 Test Preparation (dpeaa)DE-He213 Seilheimer, Bernd aut Enthalten in Journal of immune based therapies and vaccines London : Biomed Central, 2003 8(2010), 1 vom: 16. Nov. (DE-627)362770271 (DE-600)2100016-5 1476-8518 nnns volume:8 year:2010 number:1 day:16 month:11 https://dx.doi.org/10.1186/1476-8518-8-6 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2010 1 16 11
allfieldsGer	10.1186/1476-8518-8-6 doi (DE-627)SPR029446600 (SPR)1476-8518-8-6-e DE-627 ger DE-627 rakwb eng Roeska, Kerstin verfasserin aut Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010 Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. Respiratory Syncytial Virus (dpeaa)DE-He213 Antiviral Activity (dpeaa)DE-He213 Respiratory Virus (dpeaa)DE-He213 Antiviral Effect (dpeaa)DE-He213 Test Preparation (dpeaa)DE-He213 Seilheimer, Bernd aut Enthalten in Journal of immune based therapies and vaccines London : Biomed Central, 2003 8(2010), 1 vom: 16. Nov. (DE-627)362770271 (DE-600)2100016-5 1476-8518 nnns volume:8 year:2010 number:1 day:16 month:11 https://dx.doi.org/10.1186/1476-8518-8-6 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2010 1 16 11
allfieldsSound	10.1186/1476-8518-8-6 doi (DE-627)SPR029446600 (SPR)1476-8518-8-6-e DE-627 ger DE-627 rakwb eng Roeska, Kerstin verfasserin aut Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment 2010 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010 Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. Respiratory Syncytial Virus (dpeaa)DE-He213 Antiviral Activity (dpeaa)DE-He213 Respiratory Virus (dpeaa)DE-He213 Antiviral Effect (dpeaa)DE-He213 Test Preparation (dpeaa)DE-He213 Seilheimer, Bernd aut Enthalten in Journal of immune based therapies and vaccines London : Biomed Central, 2003 8(2010), 1 vom: 16. Nov. (DE-627)362770271 (DE-600)2100016-5 1476-8518 nnns volume:8 year:2010 number:1 day:16 month:11 https://dx.doi.org/10.1186/1476-8518-8-6 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 8 2010 1 16 11
language	English
source	Enthalten in Journal of immune based therapies and vaccines 8(2010), 1 vom: 16. Nov. volume:8 year:2010 number:1 day:16 month:11
sourceStr	Enthalten in Journal of immune based therapies and vaccines 8(2010), 1 vom: 16. Nov. volume:8 year:2010 number:1 day:16 month:11
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Respiratory Syncytial Virus Antiviral Activity Respiratory Virus Antiviral Effect Test Preparation
isfreeaccess_bool	true
container_title	Journal of immune based therapies and vaccines
authorswithroles_txt_mv	Roeska, Kerstin @@aut@@ Seilheimer, Bernd @@aut@@
publishDateDaySort_date	2010-11-16T00:00:00Z
hierarchy_top_id	362770271
id	SPR029446600
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR029446600</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519123824.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2010 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1476-8518-8-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR029446600</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1476-8518-8-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Roeska, Kerstin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Roeska and Seilheimer; licensee BioMed Central Ltd. 2010</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Syncytial Virus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiviral Activity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Virus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiviral Effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Test Preparation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seilheimer, Bernd</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of immune based therapies and vaccines</subfield><subfield code="d">London : Biomed Central, 2003</subfield><subfield code="g">8(2010), 1 vom: 16. Nov.</subfield><subfield code="w">(DE-627)362770271</subfield><subfield code="w">(DE-600)2100016-5</subfield><subfield code="x">1476-8518</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:1</subfield><subfield code="g">day:16</subfield><subfield code="g">month:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1476-8518-8-6</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2010</subfield><subfield code="e">1</subfield><subfield code="b">16</subfield><subfield code="c">11</subfield></datafield></record></collection>
author	Roeska, Kerstin
spellingShingle	Roeska, Kerstin misc Respiratory Syncytial Virus misc Antiviral Activity misc Respiratory Virus misc Antiviral Effect misc Test Preparation Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment
authorStr	Roeska, Kerstin
ppnlink_with_tag_str_mv	@@773@@(DE-627)362770271
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1476-8518
topic_title	Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment Respiratory Syncytial Virus (dpeaa)DE-He213 Antiviral Activity (dpeaa)DE-He213 Respiratory Virus (dpeaa)DE-He213 Antiviral Effect (dpeaa)DE-He213 Test Preparation (dpeaa)DE-He213
topic	misc Respiratory Syncytial Virus misc Antiviral Activity misc Respiratory Virus misc Antiviral Effect misc Test Preparation
topic_unstemmed	misc Respiratory Syncytial Virus misc Antiviral Activity misc Respiratory Virus misc Antiviral Effect misc Test Preparation
topic_browse	misc Respiratory Syncytial Virus misc Antiviral Activity misc Respiratory Virus misc Antiviral Effect misc Test Preparation
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Journal of immune based therapies and vaccines
hierarchy_parent_id	362770271
hierarchy_top_title	Journal of immune based therapies and vaccines
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)362770271 (DE-600)2100016-5
title	Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment
ctrlnum	(DE-627)SPR029446600 (SPR)1476-8518-8-6-e
title_full	Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment
author_sort	Roeska, Kerstin
journal	Journal of immune based therapies and vaccines
journalStr	Journal of immune based therapies and vaccines
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2010
contenttype_str_mv	txt
author_browse	Roeska, Kerstin Seilheimer, Bernd
container_volume	8
format_se	Elektronische Aufsätze
author-letter	Roeska, Kerstin
doi_str_mv	10.1186/1476-8518-8-6
title_sort	antiviral activity of $ engystol^{®} $ and gripp-$ heel^{®} $: an in-vitro assessment
title_auth	Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment
abstract	Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010
abstractGer	Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010
abstract_unstemmed	Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response. © Roeska and Seilheimer; licensee BioMed Central Ltd. 2010
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment
url	https://dx.doi.org/10.1186/1476-8518-8-6
remote_bool	true
author2	Seilheimer, Bernd
author2Str	Seilheimer, Bernd
ppnlink	362770271
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/1476-8518-8-6
up_date	2024-07-04T01:00:25.133Z
_version_	1803608208320757760
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR029446600</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519123824.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2010 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1476-8518-8-6</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR029446600</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)1476-8518-8-6-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Roeska, Kerstin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2010</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Roeska and Seilheimer; licensee BioMed Central Ltd. 2010</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Infections with respiratory viruses can activate the innate immune response - an important host defence mechanism in the early stage of viral infection. Interferon (IFN) release, triggered by virus infection, is an important factor in establishing an antiviral state, where IFN activation occurs prior to the onset of the adaptive immune response. The two ultra-low-dose combination medications, $ Engystol^{®} $ and Gripp-$ Heel^{®} $, have documented efficacy for the treatment of the respiratory infections. However, the underlying antiviral mechanisms remain elusive. Methods It was the goal to investigate whether $ Engystol^{®} $ and Gripp-$ Heel^{®} $ display antiviral activity in a prophylactic treatment protocol (2, 24 and 48 h pre-incubation) using a plaque reduction assay and whether the medications affect the release of type 1 IFN in virus-susceptible cell lines and human peripheral blood mononuclear cells (PBMCs). Results Both medications demonstrate prophylactic effect against viral respiratory virus replication. However, when the incubation was continued for up to 5 days, both medications exhibited a pronounced antiviral effect which was dependent on the pre-incubation time. Moreover, in co-stimulated HeLa cells as well as in activated PBMCs Gripp-$ Heel^{®} $ and $ Engystol^{®} $ demonstrated an increased type 1 IFN production. Conclusions $ Engystol^{®} $ and Gripp-$ Heel^{®} $ inhibited the replication of a variety of respiratory viruses. Additionally, we showed that pre-incubation affects the magnitude of the inhibitory effect differently for the various tested viruses. Both medications stimulate type 1 IFN release in different cell systems which suggests that their antiviral activity may be mediated possibly via modulation of the antiviral type 1 IFN host response.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Syncytial Virus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiviral Activity</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Respiratory Virus</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antiviral Effect</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Test Preparation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Seilheimer, Bernd</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of immune based therapies and vaccines</subfield><subfield code="d">London : Biomed Central, 2003</subfield><subfield code="g">8(2010), 1 vom: 16. Nov.</subfield><subfield code="w">(DE-627)362770271</subfield><subfield code="w">(DE-600)2100016-5</subfield><subfield code="x">1476-8518</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:8</subfield><subfield code="g">year:2010</subfield><subfield code="g">number:1</subfield><subfield code="g">day:16</subfield><subfield code="g">month:11</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/1476-8518-8-6</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">8</subfield><subfield code="j">2010</subfield><subfield code="e">1</subfield><subfield code="b">16</subfield><subfield code="c">11</subfield></datafield></record></collection>
score	7.401453

Nicht das Richtige dabei?

Schreiben Sie uns!

Antiviral activity of $ Engystol^{®} $ and Gripp-$ Heel^{®} $: an in-vitro assessment

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?